Clinical Discovery



Clinical Discovery Program


The purpose of the Clinical Discovery Program is to rapidly translate and test novel diagnostic and therapeutic approaches from bench to bedside. This Program focuses primarily on technologies previously developed at CSB but also applies other new technologies as they are related to human biology. The primary fields of interest are currently in cancer dx, clinical imaging and systems analyses. Investigators in this program are practicing clinician scientists from Massachusetts General Hospital and collaborators from other Harvard Medical School teaching hospitals. The program is primarily funded through grants from NIH.

Recent Publications (more...)

Frenk NE, Spring L, Muzikansky A, Vadvala HV Gurski JM Jr, Henderson LE, Mino-Kenudson M, Ly A, Bardia A, Finkelstein D, Engelman J, Mueller PR, Juric D, Weissleder R
High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors
JCO Precis Oncol. 2017;1:1-9
Global Cardiovascular Magnetic Resonance Registry (GCMR) Investigators, Kwong RY, Petersen SE, Schulz-Menger J, Arai AE, Bingham SE, Chen Y, Choi YL, Cury RC, Ferreira VM, Flamm SD, Steel K, Bandettini WP, Martin ET, Nallamshetty L, Neubauer S, Raman SV, Schelbert EB, Valeti US, Cao JJ, Reichek N, Young AA, Fexon L, Pivovarov M, Ferrari VA, Simonetti OP
The global cardiovascular magnetic resonance registry (GCMR) of the society for cardiovascular magnetic resonance (SCMR): its goals, rationale, data infrastructure, and current developments.
J Cardiovasc Magn Reson. 2017;19(1):23 - PMID: 28187739 - PMCID: PMC5303267 - DOI: 10.1186/s12968-016-0321-7